Literature DB >> 23063029

Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions.

Neda Rasouli1, Stacey Seggelke, Joanna Gibbs, R Matthew Hawkins, Matthew L Casciano, Elizabeth Cohlmia, Jennifer Taylor-Cousar, Cecilia Wang, Rocio Pereira, Elisa Hsia, Boris Draznin.   

Abstract

BACKGROUND: With improved longevity, cystic fibrosis (CF)-related diabetes (CFRD) has emerged as the most common nonpulmonary complication of CF. Patients with CFRD are frequently admitted to the hospital with infections and deterioration of pulmonary function, during which time glycemic control might have an impact on pulmonary function, recovery from infection, and survival. METHODS AND
RESULTS: In an attempt to share our insight into inpatient management of CFRD, this article summarizes the experience of our inpatient glucose management team with hospital management of 121 adult CFRD patients who were hospitalized on 410 occasions at the University of Colorado Hospital between January 2009 and September 2011. This is a retrospective chart review descriptive study of inpatient management of CFRD in our center. Our cohort includes CFRD patients treated with basal and mealtime insulin through multiple daily injections or continuous subcutaneous insulin infusion (CSII), as well as patients receiving steroids or enteral nutrition, which adds complexity to the management of CFRD during hospitalization.
CONCLUSIONS: Multiple hospitalizations and intensive inpatient management of CF are integral elements of treatment. Inpatient therapy for CFRD requires a customized approach that is uniquely different from that of type 1 or type 2 diabetes. Our experience highlights clinical circumstances such as irregular food intake, high dose steroid therapy, and supplemental tube feeding. For many patients, it is possible to continue CSII therapy during hospitalization through a combination of mutual trust between the patient and hospital staff and oversight provided by the glucose management team.
© 2012 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063029      PMCID: PMC3570837          DOI: 10.1177/193229681200600507

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  35 in total

Review 1.  Recent trends in cystic fibrosis-related diabetes.

Authors:  Brandon M Nathan; Theresa Laguna; Antoinette Moran
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-08       Impact factor: 3.243

2.  Treatment recommendations for cystic fibrosis-related diabetes: too little, too late?

Authors:  Brandon Nathan; Antoinette Moran
Journal:  Thorax       Date:  2011-05-04       Impact factor: 9.139

3.  Use of continuous glucose monitoring to estimate insulin requirements in patients with type 1 diabetes mellitus during a short course of prednisone.

Authors:  Wendy C Bevier; Howard C Zisser; Lois Jovanovic; Daniel A Finan; Cesar C Palerm; Dale E Seborg; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2008-07

4.  Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy.

Authors:  Elisa Hsia; Stacey A Seggelke; Joanna Gibbs; Neda Rasouli; Boris Draznin
Journal:  Nutr Clin Pract       Date:  2011-12       Impact factor: 3.080

5.  Epidemiology of cystic fibrosis-related diabetes.

Authors:  B C Marshall; S M Butler; M Stoddard; A M Moran; T G Liou; W J Morgan
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

6.  Longitudinal evaluation of glucose tolerance and insulin secretion in non-diabetic children and adolescents with cystic fibrosis: results of a two-year follow-up.

Authors:  T Arrigo; D Cucinotta; S Conti Nibali; E Di Cesare; A Di Benedetto; G Magazzù; F De Luca
Journal:  Acta Paediatr       Date:  1993-03       Impact factor: 2.299

7.  Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis.

Authors:  Elise Bismuth; Kathleen Laborde; Pierre Taupin; Gilberto Velho; Virginie Ribault; Farida Jennane; Etienne Grasset; Isabelle Sermet; Jacques de Blic; Gérard Lenoir; Jean-Jacques Robert
Journal:  J Pediatr       Date:  2007-11-26       Impact factor: 4.406

8.  Impaired fasting glucose in cystic fibrosis.

Authors:  Brigitte I Frohnert; Katie Larson Ode; Antoinette Moran; Brandon M Nathan; Theresa Laguna; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

9.  Correlation between genotype and phenotype in patients with cystic fibrosis.

Authors: 
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

10.  Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia.

Authors:  F Lombardo; F De Luca; M Rosano; C Sferlazzas; C Lucanto; T Arrigo; M F Messina; G Crisafulli; M Wasniewska; M Valenzise; D Cucinotta
Journal:  Eur J Endocrinol       Date:  2003-07       Impact factor: 6.664

View more
  2 in total

Review 1.  Auxological and Endocrinological Features in Children and Adolescents with Cystic Fibrosis.

Authors:  Vittorio Ferrari; Vito Terlizzi; Stefano Stagi
Journal:  J Clin Med       Date:  2022-07-13       Impact factor: 4.964

Review 2.  A Practical Approach to Glucose Abnormalities in Cystic Fibrosis.

Authors:  Gregory C Jones; Christopher A R Sainsbury
Journal:  Diabetes Ther       Date:  2016-10-17       Impact factor: 2.945

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.